These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

691 related items for PubMed ID: 20471231

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. New tuberculosis vaccines.
    Martín Montañés C, Gicquel B.
    Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 1():57-62. PubMed ID: 21420568
    [Abstract] [Full Text] [Related]

  • 4. Antituberculous vaccine development: a perspective for the endemic world.
    Verma I, Grover A.
    Expert Rev Vaccines; 2009 Nov; 8(11):1547-53. PubMed ID: 19863247
    [Abstract] [Full Text] [Related]

  • 5. Advances in tuberculosis vaccine strategies.
    Skeiky YA, Sadoff JC.
    Nat Rev Microbiol; 2006 Jun; 4(6):469-76. PubMed ID: 16710326
    [Abstract] [Full Text] [Related]

  • 6. Fusion protein Ag85B-MPT64(190-198)-Mtb8.4 has higher immunogenicity than Ag85B with capacity to boost BCG-primed immunity against Mycobacterium tuberculosis in mice.
    Luo Y, Wang B, Hu L, Yu H, Da Z, Jiang W, Song N, Qie Y, Wang H, Tang Z, Xian Q, Zhang Y, Zhu B.
    Vaccine; 2009 Oct 19; 27(44):6179-85. PubMed ID: 19712772
    [Abstract] [Full Text] [Related]

  • 7. MVA-85A, a novel candidate booster vaccine for the prevention of tuberculosis in children and adults.
    Nicol MP, Grobler LA.
    Curr Opin Mol Ther; 2010 Feb 19; 12(1):124-34. PubMed ID: 20140824
    [Abstract] [Full Text] [Related]

  • 8. Future vaccination strategies against tuberculosis: thinking outside the box.
    Kaufmann SH.
    Immunity; 2010 Oct 29; 33(4):567-77. PubMed ID: 21029966
    [Abstract] [Full Text] [Related]

  • 9. Heterologous boost vaccines for bacillus Calmette-Guérin prime immunization against tuberculosis.
    Xing Z, Charters TJ.
    Expert Rev Vaccines; 2007 Aug 29; 6(4):539-46. PubMed ID: 17669008
    [Abstract] [Full Text] [Related]

  • 10. Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis.
    Sun R, Skeiky YA, Izzo A, Dheenadhayalan V, Imam Z, Penn E, Stagliano K, Haddock S, Mueller S, Fulkerson J, Scanga C, Grover A, Derrick SC, Morris S, Hone DM, Horwitz MA, Kaufmann SH, Sadoff JC.
    Vaccine; 2009 Jul 16; 27(33):4412-23. PubMed ID: 19500523
    [Abstract] [Full Text] [Related]

  • 11. Interaction of Mycobacterium tuberculosis with the host: consequences for vaccine development.
    Dietrich J, Doherty TM.
    APMIS; 2009 May 16; 117(5-6):440-57. PubMed ID: 19400867
    [Abstract] [Full Text] [Related]

  • 12. Selection of novel TB vaccine candidates and their evaluation as DNA vaccines against aerosol challenge.
    Vipond J, Vipond R, Allen-Vercoe E, Clark SO, Hatch GJ, Gooch KE, Bacon J, Hampshire T, Shuttleworth H, Minton NP, Blake K, Williams A, Marsh PD.
    Vaccine; 2006 Sep 11; 24(37-39):6340-50. PubMed ID: 16781800
    [Abstract] [Full Text] [Related]

  • 13. The use of mutant mycobacteria as new vaccines to prevent tuberculosis.
    Hernàndez Pando R, Aguilar LD, Infante E, Cataldi A, Bigi F, Martin C, Gicquel B.
    Tuberculosis (Edinb); 2006 Sep 11; 86(3-4):203-10. PubMed ID: 16542875
    [Abstract] [Full Text] [Related]

  • 14. The second Geneva Consensus: Recommendations for novel live TB vaccines.
    Walker KB, Brennan MJ, Ho MM, Eskola J, Thiry G, Sadoff J, Dobbelaer R, Grode L, Liu MA, Fruth U, Lambert PH.
    Vaccine; 2010 Mar 08; 28(11):2259-70. PubMed ID: 20074686
    [Abstract] [Full Text] [Related]

  • 15. Tuberculosis: vaccines in the pipeline.
    Ly LH, McMurray DN.
    Expert Rev Vaccines; 2008 Jul 08; 7(5):635-50. PubMed ID: 18564018
    [Abstract] [Full Text] [Related]

  • 16. Prospects for a novel vaccine against tuberculosis.
    Dietrich J, Weldingh K, Andersen P.
    Vet Microbiol; 2006 Feb 25; 112(2-4):163-9. PubMed ID: 16325357
    [Abstract] [Full Text] [Related]

  • 17. Immunoprophylaxis of tuberculosis: an update of emerging trends.
    Singhal N, Bisht D, Joshi B.
    Arch Immunol Ther Exp (Warsz); 2010 Apr 25; 58(2):97-106. PubMed ID: 20140756
    [Abstract] [Full Text] [Related]

  • 18. Enhanced protection against tuberculosis by vaccination with recombinant Mycobacterium microti vaccine that induces T cell immunity against region of difference 1 antigens.
    Brodin P, Majlessi L, Brosch R, Smith D, Bancroft G, Clark S, Williams A, Leclerc C, Cole ST.
    J Infect Dis; 2004 Jul 01; 190(1):115-22. PubMed ID: 15195250
    [Abstract] [Full Text] [Related]

  • 19. The safety of post-exposure vaccination of mice infected with Mycobacterium tuberculosis.
    Derrick SC, Perera LP, Dheenadhayalan V, Yang A, Kolibab K, Morris SL.
    Vaccine; 2008 Nov 11; 26(48):6092-8. PubMed ID: 18809446
    [Abstract] [Full Text] [Related]

  • 20. An attenuated Salmonella-vectored vaccine elicits protective immunity against Mycobacterium tuberculosis.
    Wang QL, Pan Q, Ma Y, Wang K, Sun P, Liu S, Zhang XL.
    Vaccine; 2009 Nov 12; 27(48):6712-22. PubMed ID: 19733584
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.